What it sells
Cancer tests based on whole genome and transcriptome data.
Business model breakdown
Buyer: who owns the budget?
UnverifiedHospital cancer centers and biopharma companion-diagnostic teams.
Trigger: what makes them buy now?
Panel tests detect few genes, leaving many patients without clinically relevant findings.
Workflow: what inputs become what output?
Sample, sequencing, analysis, report: biopsy to actionable report in clinically relevant timeframes.
Distribution: how it reaches customers
Contact/meeting driven; WGTS SaaS offered via scheduled meetings.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2020 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.